Aprea Therapeutics, Inc. (APRE) vs Quince Therapeutics, Inc. (QNCX)
A side-by-side comparison of Aprea Therapeutics, Inc. and Quince Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APRE
Aprea Therapeutics, Inc.
$0.64HealthcareDelayed quote: Oct 6, 2026, 2:44 PM EDT
QNCX
Quince Therapeutics, Inc.
$27.45HealthcareDelayed quote: Oct 6, 2026, 2:43 PM EDT
Total return — APRE vs QNCX
growth of $100 · dividends reinvested · last 7yAPRE -99.8% (-60.0%/yr)QNCX -99.4% (-51.8%/yr)QNCX compounded faster over this window
APRE QNCX
APRE vs QNCX: by the numbers
- •APRE is the larger company ($8M vs $8M market cap).
Metrics side by side
Valuation
| Metric | APRE | QNCX |
|---|---|---|
| P/B ratio | 0.21 | N/A |
Profitability
| Metric | APRE | QNCX |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -31.99% | -85.24% |
| ROIC | -33.73% | -107.08% |
Growth (annualized)
| Metric | APRE | QNCX |
|---|---|---|
| Total return CAGR (5Y) | -63.30% | -72.96% |
Frequently asked
- How have APRE and QNCX total returns compared?
- Over the past 5 years, APRE delivered -63.30% and QNCX delivered -72.96% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.